ORGOVYX® is a prescription-only medicine that contains the active substance relugolix. It is used for:

For the treatment of adult patients with advanced hormone-sensitive prostate cancer.¹
For the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.¹
As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer¹

What is prostate cancer?

Prostate cancer is a cancer that forms in the cells of the prostate, a walnut-sized gland that sits at the base of your bladder.²

Prostate cancer develops when cells in the prostate start to grow uncontrollably; this is due to the growth of abnormal cells that do not behave like normal cells. These cancer cells can mutate and multiply to create more cancer cells, causing the cancer to grow, crowd out and overpower normal cells.^3,4

Doctors often describe prostate cancer based on its stage; this considers the location of the cancer, whether it has spread (metastasised) and how much it’s interfering with normal body processes.⁵

What is prostate cancer?

Prostate cancer is a cancer that forms in the cells of the prostate, a walnut-sized gland that sits at the base of your bladder.²

Want to find out more about ORGOVYX®?

The below resources contain important and helpful information on prostate cancer and treatment with ORGOVYX®.

ORGOVYX® patient guide

This guide contains important information about ORGOVYX® (relugolix) that you and your family can download and save.

ORGOVYX® patient information leaflet

This leaflet provides useful information on taking your medicine.

Adverse events should be reported.

Side Effects should be reported. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. Adverse events should also be reported to Accord-UK Ltd Medical Information on 01271 385257.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

References

Orgovyx® Package Leaflet.
Cancer Research UK. 2019. What is hormone therapy for prostate cancer? Available from: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/about (Accessed May 2024).
Prostate Cancer Foundation. 2021. Prostate Cancer Patient Guide. Available from: https://res.cloudinary.com/pcf/image/upload/v1651273711/PCF_PatientGuide_Apr2022_negisa.pdf (Accessed May 2024).
National Comprehensive Cancer Network. 2022. Prostate Cancer Early Stage. Available from: https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf (Accessed May 2024).
Prostate Cancer Foundation. Prostate Cancer Staging. Available from: https://www.pcf.org/about-prostate-cancer/diagnosis-staging-prostate-cancer/prostate-cancer-staging/ (Accessed May 2024).

References

Orgovyx® Package Leaflet.
Cancer Research UK. 2019. What is hormone therapy for prostate cancer? Available from: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/about (Accessed May 2024).
Prostate Cancer Foundation. 2021. Prostate Cancer Patient Guide. Available from: https://res.cloudinary.com/pcf/image/upload/v1651273711/PCF_PatientGuide_Apr2022_negisa.pdf (Accessed May 2024).
National Comprehensive Cancer Network. 2022. Prostate Cancer Early Stage. Available from: https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf (Accessed May 2024).
Prostate Cancer Foundation. Prostate Cancer Staging. Available from: https://www.pcf.org/about-prostate-cancer/diagnosis-staging-prostate-cancer/prostate-cancer-staging/ (Accessed May 2024).